372 related articles for article (PubMed ID: 17620054)
21. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
22. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.
Garnero P; Sornay-Rendu E; Claustrat B; Delmas PD
J Bone Miner Res; 2000 Aug; 15(8):1526-36. PubMed ID: 10934651
[TBL] [Abstract][Full Text] [Related]
23. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.
Delmas PD; Marianowski L; Perez Ade C; Ribot C; Pornel B; Palacios S; Lopes P;
Maturitas; 2004 Jun; 48(2):85-96. PubMed ID: 15172082
[TBL] [Abstract][Full Text] [Related]
24. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
25. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
[TBL] [Abstract][Full Text] [Related]
26. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
[TBL] [Abstract][Full Text] [Related]
27. Endogenous sex steroids and bone mineral density in healthy Greek postmenopausal women.
Lambrinoudaki I; Christodoulakos G; Aravantinos L; Antoniou A; Rizos D; Chondros C; Kountouris A; Chrysofakis G; Creatsas G
J Bone Miner Metab; 2006; 24(1):65-71. PubMed ID: 16369901
[TBL] [Abstract][Full Text] [Related]
28. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
29. Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women.
García-Pérez MA; Moreno-Mercer J; Tarín JJ; Cano A
Gynecol Endocrinol; 2006 Apr; 22(4):179-84. PubMed ID: 16723303
[TBL] [Abstract][Full Text] [Related]
30. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
Bone HG; Greenspan SL; McKeever C; Bell N; Davidson M; Downs RW; Emkey R; Meunier PJ; Miller SS; Mulloy AL; Recker RR; Weiss SR; Heyden N; Musliner T; Suryawanshi S; Yates AJ; Lombardi A
J Clin Endocrinol Metab; 2000 Feb; 85(2):720-6. PubMed ID: 10690882
[TBL] [Abstract][Full Text] [Related]
31. Treatment of postmenopausal osteoporosis with transdermal estrogen.
Lufkin EG; Wahner HW; O'Fallon WM; Hodgson SF; Kotowicz MA; Lane AW; Judd HL; Caplan RH; Riggs BL
Ann Intern Med; 1992 Jul; 117(1):1-9. PubMed ID: 1534476
[TBL] [Abstract][Full Text] [Related]
32. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
33. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Recker RR; Benson CT; Matsumoto T; Bolognese MA; Robins DA; Alam J; Chiang AY; Hu L; Krege JH; Sowa H; Mitlak BH; Myers SL
J Bone Miner Res; 2015 Feb; 30(2):216-24. PubMed ID: 25196993
[TBL] [Abstract][Full Text] [Related]
35. Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.
Cooper C; Stakkestad JA; Radowicki S; Hardy P; Pilate C; Dain MP; Delmas PD
Osteoporos Int; 1999; 9(4):358-66. PubMed ID: 10550454
[TBL] [Abstract][Full Text] [Related]
36. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate].
Collette J; Viethel P; Dethor M; Chevallier T; Micheletti MC; Foidart JM; Reginster JY
Gynecol Obstet Fertil; 2003 May; 31(5):434-41. PubMed ID: 14567121
[TBL] [Abstract][Full Text] [Related]
38. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
Nielsen TF; Ravn P; Bagger YZ; Warming L; Christiansen C
Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
[TBL] [Abstract][Full Text] [Related]
39. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
Dane C; Dane B; Cetin A; Erginbas M
Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
[TBL] [Abstract][Full Text] [Related]
40. Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial.
Komulainen M; Kröger H; Tuppurainen MT; Heikkinen AM; Honkanen R; Saarikoski S
Osteoporos Int; 2000; 11(3):211-8. PubMed ID: 10824236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]